If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Opening parliament on 9 June, Gibbs told the Legislative Assembly in his speech from the throne that the RF's strengthened majority amounted to "a mandate to lead the country to its full independence", and announced that the new government had informed him of its intent to open its own diplomatic mission in Lisbon, separate from the British embassy there. The British and Rhodesians argued about this unilateral act by Salisbury, described by the historian J R T Wood as the "veritable straw in the wind", alongside the independence issue until Portugal accepted the mission in late September, much to Britain's fury and Rhodesia's delight. Hoping to bring Smith to heel by stonewalling him, Wilson's ministers deliberately delayed and frustrated the Rhodesian government in negotiations. Rhodesia was again excluded from the Commonwealth Prime Ministers' Conference in 1965. The UK's refusal of aid, the Lisbon mission, the informal arms embargo and other issues combined with this to cause the Rhodesian government's sense of alienation from Britain and the Commonwealth to deepen. In his memoirs, Smith accused the British of "resorting to politics of convenience and appeasement". Wilson, meanwhile, became exasperated by what he saw as Rhodesian inflexibility, describing the gap between the two governments as "between different worlds and different centuries".
The endosteum (pl.: endostea) is a thin vascular membrane of connective tissue that lines the inner surface of the bony tissue that forms the medullary cavity of long bones. This endosteal surface is usually resorbed during long periods of malnutrition, resulting in less cortical thickness. The outer surface of a bone is lined by a thin layer of connective tissue that is very similar in morphology and function to endosteum. It is called the periosteum, or the periosteal surface. During bone growth, the width of the bone increases as osteoblasts lay new bone tissue at the periosteum. To prevent the bone from becoming unnecessarily thick, osteoclasts resorb the bone from the endosteal side.
== References == Hunter, R. L.; Merkert, C.L. (1957). "Histochemical demonstration of enzymes separated by zone electrophoresis in starch gels". Science. 125 (3261): 1294–1295. doi:10.1126/science.125.3261.1294-a. PMID 13432800. Weiss, B.; Hait, W.N. (1977). "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents". Annu. Rev. Pharmacol. Toxicol. 17: 441–477. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360. Wendel, JF, and NF Weeden. 1990. "Visualisation and interpretation of plant isozymes." pp. 5–45 in D. E. Soltis and P. S. Soltis, eds. Isozymes in plant biology. Chapman and Hall, London. Weeden, NF, and JF Wendel. 1990. "Genetics of plant isozymes". pp. 46–72 in D. E. Soltis and P. S. Soltis, eds. Isozymes in plant biology. Chapman and Hall, London Crawford, DJ. 1989. "Enzyme electrophoresis and plant systematics". pp. 146–164 in D. E. Soltis and P. S. Soltis, eds. Isozymes in plant biology. Dioscorides, Portland, Oregon. Hamrick, JL, and MJW Godt. 1990. "Allozyme diversity in plant species". pp. 43–63 in A. H. D. Brown, M. T. Clegg, A. L. Kahler and B. S. Weir, eds. Plant Population Genetics, Breeding, and Genetic Resources. Sinauer, Sunderland Biochemistry by jeremy M. Berg, John L. Tymoczko, Lubert Stryer (Intro taken from this textbook) Specific
A replica of the San Juan Bautista was reconstructed in 1993 on the basis of the records of the House of Date. Although its blueprints have not been found, the ship's dimensions were recorded properly, permitting a speculative reconstitution. The ship was put on display in the Miyagi Sant Juan Bautista Museum in Ishinomaki, in northern Japan, close to the location where she was originally built. The replica survived the 2011 Tōhoku earthquake and tsunami with some damage, and there were hopes in 2011 of using the ship as a symbol of the town's reconstruction. In November 2013 the repaired San Juan Bautista was rededicated. Assistance had come from Western Forest Products, a British Columbia lumber company, who supplied the massive Douglas fir and cedar logs to create masts that had been damaged in the tsunami. However, the replica ship was deemed to be unsafe to the public due to structural damage from floodwater and other factors, and the Miyagi prefectural government decided to demolish the ship rather than to continue repairing it. Dismantling began in November 2021. The government built a new ship in its place, using fibre-reinforced plastic and reducing the size to one quarter of the original. The new, smaller ship was revealed to the public in October 2024.
Sources: en.wikipedia.org
Law enforcement and intelligence agencies in a number of countries arrested alleged terrorists. British Prime Minister Tony Blair said Britain stood "shoulder to shoulder" with the United States. In a speech to Congress nine days after the attacks, which Blair attended as a guest, President Bush declared "America has no truer friend than Great Britain." Subsequently, Prime Minister Blair embarked on two months of diplomacy to rally international support for military action; he held 54 meetings with world leaders. The U.S. set up the Guantanamo Bay detention camp to hold inmates they defined as "illegal enemy combatants." The legitimacy of these detentions has been questioned by the European Union and human rights organizations. On September 25, 2001, Iran's president Mohammad Khatami, meeting British Foreign Secretary Jack Straw, said: "Iran fully understands the feelings of the Americans about the terrorist attacks in New York and Washington on September 11." He said although the American administrations had been at best indifferent about terrorist operations in Iran, the Iranians felt differently and had expressed their sympathetic feelings with bereaved Americans in the tragic incidents in the two cities.
== Applications == As of 2021 no DNA vaccines have been approved for human use in the United States. Few experimental trials have evoked a response strong enough to protect against disease and the technique's usefulness remains to be proven in humans. A veterinary DNA vaccine to protect horses from West Nile virus has been approved. Another West Nile virus vaccine has been tested successfully on American robins. DNA immunization is also being investigated as a means of developing antivenom sera. DNA immunization can be used as a technology platform for monoclonal antibody induction.
== Biomedical use == Its bell collagen is currently being researched for use as an intercellular matrix. The collagen is made up of 1/3 glycine and most of the rest is water and other amino acids, its amino acid content is very small. The collagen is denatured as soon as it reaches 29.9 °C (85.8 °F).
Sources: en.wikipedia.org
== Putative SLCs == Putative SLCs, also called atypical SLCs, are novel, plausible secondary active or facilitative transporter proteins that share ancestral background with the known SLCs. The atypical SLCs of MFS type can, however, be subdivided into 15 Putative MFS Transporter Families (AMTF). All the putative SLCs are plausible SLC transporters. Some are only "atypical" when it comes to their nomenclature; the genes have an SLC assignment but as an alias, and have retained their already assigned "non-SLC" gene symbol as the approved symbol. Here are some Putative SLCs listed: OCA2, CLN3, TMEM104, SPNS1, SPNS2, SPNS3, SV2A, SV2B, SV2C, SVOP, SVOPL, MFSD1, MFSD2A, MFSD2B, MFSD3, MFSD4A, MFSD4B, MFSD5, MFSD6, MFSD6L, MFSD8, MFSD9, MFSD10, MFSD11, MFSD12, MFSD13A, MFSD14A, MFSD14B, UNC93A and UNC93B1.
Masterton and Slowinski used three criteria to describe the six elements commonly recognised as metalloids: metalloids have ionization energies around 200 kcal/mol (837 kJ/mol) and electronegativity values close to 2.0. They also said that metalloids are typically semiconductors, though antimony and arsenic (semimetals from a physics perspective) have electrical conductivities approaching those of metals. Selenium and polonium are suspected as not in this scheme, while astatine's status is uncertain. In this context, Vernon proposed that a metalloid is a chemical element that, in its standard state, has (a) the electronic band structure of a semiconductor or a semimetal; and (b) an intermediate first ionization potential "(say 750−1,000 kJ/mol)"; and (c) an intermediate electronegativity (1.9–2.2).
== History and overview == Skittles were introduced in 1971 by Jack Candies, a British distributor for Mars, Incorporated. An animated television advertisement from 1974 bears the logo of the "Galaxy" company and is copyrighted by Jack Candies Ltd. Mars was granted a trademark from the U.S. Patent Office for the name Skittles in 1974. By 1979, Skittles became widely distributed throughout the U.S. In 1982, production of Skittles began in the United States. Mars' Wrigley division acquired the Skittles company in 2008. The name of the candy, Skittles, comes from the sports game of the same name, named as such for the resemblance of the sweet to items used in the game. Skittles' "taste the rainbow" theme was created by the New York ad agency D'Arcy Masius Benton & Bowles.
Also in 1893, Édouard Laguesse suggested that the islet cells of the pancreas, described as "little heaps of cells" by Paul Langerhans in 1869, might play a regulatory role in digestion. These cells were named Islets of Langerhans after the original discoverer. Soon after, it was established that the role of the pancreas in carbohydrate metabolism could be localized to the islets; Eugene Lindsay Opie (1901) confirmed this connection in relation to diabetes mellitus. In 1909, Belgian physician Jean de Mayer hypothesized that the islets secrete a substance that plays this metabolic role, and termed it insulin, from the Latin insula ('island'). Sir Edward Albert Sharpey-Schafer independently proposed the same in 1916, not knowing at the time that de Meyer had made the same suggestion a few years prior. The endocrine role of the pancreas in metabolism, and indeed the existence of insulin, was further clarified between 1921 and 1922 when a group of researchers in Toronto, including Frederick Banting, Charles Best, John MacLeod, and James Collip, were able to isolate and purify the extract.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.